Amit Anand1, Jeanette N McClintick2, Jill Murrell2, Harish Karne1, John I Nurnberger3, Howard J Edenberg2. 1. Center for Behavioral Health, Cleveland Clinic, Cleveland, Ohio, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Ind., USA. 2. Department of Biochemistry and Molecular Biology and Center for Medical Genomics, Indiana University School of Medicine, Indianapolis, Ind., USA. 3. Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Ind., USA.
Abstract
BACKGROUND: This study investigated the effect of lithium monotherapy on peripheral lymphocyte gene expression in bipolar disorder (BD). METHOD: Twenty-two medication-free bipolar subjects (11 hypomanic, 11 depressed) were started on lithium monotherapy. Closely matched healthy subjects (n = 15) were included as controls but did not receive treatment. Blood RNA samples were collected at baseline and after 2 and 8 weeks of treatment. RNA expression was measured using the Affymetrix GeneChip® Human Gene 1.0 ST Array followed by Ingenuity pathways analysis. The results for the contrast of weeks 2 and 8 were not significantly different and were combined. RESULTS: In BD subjects, 56 genes showed significant (false discovery rate <0.1) expression changes from baseline; the effect sizes and directions for all of these were similar at weeks 2 and 8. Among these were immune-related genes (IL5RA, MOK, IFI6, and RFX2), purinergic receptors (P2RY14, P2RY2, and ADORA3) and signal transduction-related genes (CAMK1 and PIK3R6). Pathway and upstream regulator analysis also revealed that lithium altered several immune- and signal transduction-related functions. Differentially expressed genes did not correlate with week 8 clinical response, but other genes involved in protein synthesis and degradation did. CONCLUSION: Peripheral gene expression may serve as a biomarker of lithium effect.
BACKGROUND: This study investigated the effect of lithium monotherapy on peripheral lymphocyte gene expression in bipolar disorder (BD). METHOD: Twenty-two medication-free bipolar subjects (11 hypomanic, 11 depressed) were started on lithium monotherapy. Closely matched healthy subjects (n = 15) were included as controls but did not receive treatment. Blood RNA samples were collected at baseline and after 2 and 8 weeks of treatment. RNA expression was measured using the Affymetrix GeneChip® Human Gene 1.0 ST Array followed by Ingenuity pathways analysis. The results for the contrast of weeks 2 and 8 were not significantly different and were combined. RESULTS: In BD subjects, 56 genes showed significant (false discovery rate <0.1) expression changes from baseline; the effect sizes and directions for all of these were similar at weeks 2 and 8. Among these were immune-related genes (IL5RA, MOK, IFI6, and RFX2), purinergic receptors (P2RY14, P2RY2, and ADORA3) and signal transduction-related genes (CAMK1 and PIK3R6). Pathway and upstream regulator analysis also revealed that lithium altered several immune- and signal transduction-related functions. Differentially expressed genes did not correlate with week 8 clinical response, but other genes involved in protein synthesis and degradation did. CONCLUSION: Peripheral gene expression may serve as a biomarker of lithium effect.
Authors: Francesca Bosetti; Ruth Seemann; Jane M Bell; Robert Zahorchak; Elliott Friedman; Stanley I Rapoport; Pachiappan Manickam Journal: Brain Res Bull Date: 2002-01-15 Impact factor: 4.077
Authors: R D Beech; J J Leffert; A Lin; L G Sylvia; S Umlauf; S Mane; H Zhao; C Bowden; J R Calabrese; E S Friedman; T A Ketter; D V Iosifescu; N A Reilly-Harrington; M Ostacher; M E Thase; A Nierenberg Journal: Pharmacogenomics J Date: 2013-05-14 Impact factor: 3.550
Authors: Krzysztof Pietruczuk; Katarzyna A Lisowska; Karol Grabowski; Jerzy Landowski; Jacek M Witkowski Journal: Sci Rep Date: 2018-02-20 Impact factor: 4.379
Authors: David Stacey; K Oliver Schubert; Scott R Clark; Azmeraw T Amare; Elena Milanesi; Carlo Maj; Susan G Leckband; Tatyana Shekhtman; John R Kelsoe; David Gurwitz; Bernhard T Baune Journal: Transl Psychiatry Date: 2018-09-05 Impact factor: 6.222
Authors: Ibrahim A Akkouh; Silje Skrede; Asbjørn Holmgren; Kari M Ersland; Lars Hansson; Shahram Bahrami; Ole A Andreassen; Vidar M Steen; Srdjan Djurovic; Timothy Hughes Journal: Neuropsychopharmacology Date: 2019-10-25 Impact factor: 7.853
Authors: Carlos Spuch; Marta López-García; Tania Rivera-Baltanás; Daniela Rodrígues-Amorím; José M Olivares Journal: Front Pharmacol Date: 2020-08-27 Impact factor: 5.810